FDA Oncology Announcements

Anti-CD20 × Other × Clear all

10 Announcements

FDA approves rituximab plus chemotherapy for pediatric cancer indications

Drug: Rituxan (rituximab) · Anti-CD20 antibody
Condition: Other neoplasm

Obinutuzumab

Drugs: Gazyva (obinutuzumab) · Anti-CD20 antibody, chlorambucil · Nitrogen mustard

Ofatumumab (Arzerra Injection)

Drug: Arzerra (ofatumumab) · Anti-CD20 antibody

Idelalisib

Drugs: Zydelig tablets (idelalisib) · PI3K delta inhibitor, rituximab · Anti-CD20 antibody

FDA Approves Ofatumumab

Drugs: Arzerra (ofatumumab) · Anti-CD20 antibody, chlorambucil · Nitrogen mustard

Gazyva (obinutuzumab)

Drugs: GAZYVA (obinutuzumab) · Anti-CD20 antibody, chlorambucil · Nitrogen mustard

Rituximab Infusion

Drug: Rituxan (rituximab) · Anti-CD20 antibody

Rituximab 2011

Drug: Rituxan (rituximab) · Anti-CD20 antibody

Rituximab

Drug: Rituxan (rituximab) · Anti-CD20 antibody

Ofatumumab

Drug: Arzerra (ofatumumab) · Anti-CD20 antibody